Investigational drug · Phase 2
zamtocabtagene autoleucel
Also called: MB-CART2019.1
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for CAR T Cell Therapy, Mantle Cell Lymphoma (MCL), Multiple Sclerosis.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
5
Any phase or sponsor naming "zamtocabtagene autoleucel"
First trial start
2021
May 25, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "zamtocabtagene autoleucel", any sponsor or status.
Conditions studied
As listed on its trial records.
- CAR T Cell Therapy
- Mantle Cell Lymphoma (MCL)
- Multiple Sclerosis
- DLBCL - Diffuse Large B Cell Lymphoma
- B-Cell Neoplasm
- Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Relapsed Diffuse Large B Cell Lymphoma
- High Grade B-cell Lymphoma (HGBCL)
- Primary Mediastinal B-cell Lymphoma (PMBCL)
- Transformed Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Multiple sclerosis · Oncology · Hematology and blood cancers · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "zamtocabtagene autoleucel" as an intervention, largest first.
- DALY II USA/ MB-CART2019.1 for DLBCLRecruiting
Miltenyi Biomedicine GmbHIndustry
NCT04792489 · 315 participants (planned) · Start May 25, 2021 · Primary completion Dec 31, 2026
Drug: zamtocabtagene autoleucel (MB-CART2019.1); Cyclophosphamide and 2 more · For: Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma; High Grade B-cell Lymphoma (HGBCL) and 6 more
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 32 sites in all
- Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma PatientsPivotal-lookingRecruiting
Miltenyi Biomedicine GmbHIndustry
NCT04844866 · 213 participants (planned) · Start Aug 18, 2021 · Primary completion Jan 15, 2025
Drug: Standard of Care · For: Diffuse Large B-cell Lymphoma
Sites: Graz, Austria; Innsbruck, Austria; Linz, Austria · 51 sites in all
- Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCLNot yet recruiting
Miltenyi Biomedicine GmbHIndustry
NCT07569965 · 52 participants (planned) · Start Sep 2026 · Primary completion Sep 2029
Drug: zamtocabtagene autoleucel (MB-CART2019.1); Cyclophosphamide and 1 more · For: Mantle Cell Lymphoma (MCL)
- US Zamto-cel Autoimmune DiseasesRecruiting
Miltenyi Biomedicine GmbHIndustry
NCT06708845 · 48 participants (planned) · Start Jul 2026 · Primary completion Jan 2028
Drug: zamtocabtagene autoleucel; Cyclophosphamide and 1 more · For: Lupus Nephritis; Systemic Lupus Erythematosus; Systemic Sclerosis (SSc) and 1 more
Sites: Milwaukee, Wisconsin
Miltenyi Biomedicine GmbHIndustry
NCT06508931 · 31 participants (planned) · Start Aug 4, 2025 · Primary completion Dec 31, 2029
Drug: zamtocabtagene autoleucel (MB-CART2019.1) · For: B-Cell Neoplasm
Sites: Paris, France; Villejuif, France; Münster, Germany · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.
Borchmann P, van Meerten T, Iacoboni G, et al. · Lancet Oncol 2026
- Zamtocabtagene autoleucel: dual CD20-CD19 targeting for NHL.
Srinagesh HK, Muffly LS · Blood Adv 2026
- Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial.
Balke-Want H, Gödel P, Schmid C, et al. · Blood Adv 2026
- Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.
Lee D, Dahiya S · Haematologica 2026
- CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma.
Hardy NM, Yared JA, Luetkens T, et al. · Haematologica 2026
- Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel.
Szabo D, Balogh A, Gopcsa L, et al. · RMD Open 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.